What vVardis does

vVardis is a privately held Swiss dental medtech company founded in 2020 in Baar, Switzerland, by sisters and co-CEOs Dr. Haley Abivardi, DMD, and Dr. Goly Abivardi, DMD. The company commercializes a proprietary biomimetic peptide technology (P11-4), branded Curodont™, which is the first and only chairside, drill-free, needle-free, regenerative treatment for early-stage dental caries. The P11-4 self-assembling peptide diffuses into early carious lesions, halts decay progression, and rebuilds lost enamel by attracting calcium and phosphate from saliva — addressing the historical treatment gap between preventive care and conventional drilling/filling. The technology is supported by 25+ years of underlying research, 200+ clinical studies, and 230+ peer-reviewed publications, and is progressively being integrated into the curricula of prestigious dental schools.

vVardis's commercial product line consists of Curodont Repair and the enhanced Curodont Repair Fluoride Plus, applied chairside in as little as 3 minutes (US) to ~5 minutes (EU) per lesion, typically a one-time application. Revenue is generated primarily through B2B sales of the professional product to dental practices via an exclusive U.S. distribution agreement with Henry Schein across all dental segments (effective January 2026) and a UK partnership with mydentist covering ~500 practices. A secondary, smaller revenue stream comes from direct-to-consumer e-commerce on vvardis.com for the US market, with free shipping, recurring 30-day subscription options, and a 30-day return policy. As of April 2026, Curodont has been used to treat approximately 3 million teeth in the United States and is present in nearly 20% of US general dental practices.

The company has scaled rapidly: it secured $85 million in cumulative financing from OrbiMed across 2025, achieved unicorn status with a $1B+ valuation through a strategic minority investment from Apollo Global Management in April 2026 (with founders retaining ~70% ownership), and operates localized commercial sites across 12 country markets (US, UK, Switzerland, Germany, France, Italy, Austria, Spain, Poland, Czech Republic, Finland, UAE). It has also built an AI-detection ecosystem via commercial collaborations with VideaHealth (VideaAI) and Pearl, integrating AI-driven early caries detection with Curodont treatment in a same-day workflow that has processed more than 400,000 patients. As of June 2026, vVardis is exploring a U.S. IPO with JPMorgan Chase and Goldman Sachs as advisors.

Name

vVardis

Legal name

vVARDIS AG

Website

https://vvardis.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

vVardis is a Swiss dental medtech company that develops and commercializes Curodont™, a proprietary biomimetic P11-4 peptide-based drill-free treatment for early-stage tooth decay, sold to dental professionals globally through exclusive distributors and direct channels.

Ownership category

akta.pro rank

Product category

Biomimetic Dental Care

NAICS

Dental Equipment and Supplies Manufacturing (339114), Dental Laboratories (339116)

SIC

Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)

akta.pro primary industry

Cosmetic & Esthetic Dentistry (Veneers/Whitening/Bonding) (HLABAAAC)

akta.pro secondary industries

Non-Surgical Periodontal Therapy (Scaling & Root Planing) (HLABAHAJ), Desensitization Treatments for Dentin Hypersensitivity (HLABAHAK), Non-Surgical Periodontal Therapy (Scaling & Root Planing) (HLABACAA), Preventive & Routine General Dentistry (Exams/Cleanings/Sealants/Fluoride) (HLABAAAA)

Keywords

• Biomimetic dental treatment
• Drill-free cavity treatment
• Enamel remineralization products
• Peptide-based dental care
• Preventive dental technology

Headquarters

HQ city

Baar

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Dental professional / clinic product sales (via distribution partner): vVARDIS generates revenue by selling its Curodont product line (including Curodont Repair and Curodont Repair Fluoride Plus) to dental professionals and clinics. Sales in the US are channeled through Henry Schein as exclusive U.S. distributor across all dental segments (including DSOs). Pricing at the patient level in the UK is from £140 per course.
2. Direct e-commerce sales of consumer oral care products: vVARDIS operates a consumer-facing website (vvardis.com) with web shop where it sells oral care products directly to consumers with free shipping within the 50 US states, recurring order options (every 30 days), and 30-day return policy. Payment methods include Visa, MasterCard, American Express, Discover, PayPal and Apple Pay.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

vVARDIS develops and commercializes its proprietary P11-4 biomimetic self-assembling peptide technology as the Curodont™ drill-free, needle-free chairside treatment for early-stage tooth decay. The peptide diffuses into early carious lesions, halts decay progression, and regenerates enamel by attracting calcium and phosphate from saliva — without drilling, anesthesia, or traditional filling materials. Products (Curodont Repair and Curodont Repair Fluoride Plus) are sold to dental professionals through Henry Schein (exclusive U.S. distributor) and channel partners, and oral care products are sold directly to consumers via vvardis.com.

Product overview

vVARDIS offers a single core technology platform — its proprietary P11-4 biomimetic peptide technology — which is commercialized through a unified product brand, Curodont™, comprising the chairside treatment Curodont Repair and the enhanced variant Curodont Repair Fluoride Plus. The Curodont family is the drill-free, needle-free treatment for early-stage dental caries and is delivered to dental professionals through the vVARDIS Professional program and the Certified Curodontist™ certification, supported by the "Save Teeth Save Lives" global awareness campaign. Together these elements form an integrated non-invasive dental-care platform rather than a set of unrelated products.

Differentiator

Problem solved

Functional benefit

Brands

• Curodont: vVARDIS's proprietary biomimetic, peptide-based (P11-4) drill-free, needle-free dental treatment for early-stage tooth decay; includes Curodont Repair and Curodont Repair Fluoride Plus variants.
• vVARDIS Professional

Products and services

• Curodont Repair Chairside drill-free, needle-free treatment for early-stage tooth decay (caries) based on vVARDIS's proprietary P11-4 biomimetic self-assembling peptide. The peptide diffuses into early carious lesions, halts decay progression, and regenerates lost enamel minerals by attracting calcium and phosphate from saliva — without anesthesia, drilling, or traditional filling materials. Applied by dental professionals in as little as 3–10 minutes; suitable for children and adults.
• Curodont Repair Fluoride Plus Enhanced chairside drill-free treatment combining vVARDIS's P11-4 biomimetic peptide technology with fluoride for early caries management. Used in same-day workflows following AI-powered caries detection by VideaHealth, with over 400,000 patients identified and treated with a 90%+ success rate. Sold to dental professionals in the US exclusively through Henry Schein across all dental segments including DSOs.

Quantifiable outcome

• ~3 million teeth treated in the US since launch; ~20% of US general dental practices have adopted Curodont (April 2026)
• +7 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered flagship / core, core and minor.

• Henry Schein, Inc.flagship / coreChannel Partner/ Reseller/ Distributor · 1 December 2025Expanded partnership (announced December 1, 2025) makes Henry Schein the exclusive U.S. distributor of Curodont Repair Fluoride Plus across all U.S. dental segments starting January 1, 2026. Henry Schein had previously been named exclusive distributor to larger DSOs in September 2024. Henry Schein, Inc. is publicly traded on Nasdaq (HSIC), valued at approximately $9B with $12.7B in 2024 sales.
• mydentistcoreChannel Partner/ Reseller/ Distributor · 1 November 2025First-of-its-kind partnership in UK dentistry announced January 2026 covering mydentist's network of ~500 practices; Curodont Repair offered at 100 practices from November 2025 with full network rollout from 2026. Priced from £140 per course, addressing more than four million patients in mydentist's network.
• PearlcoreTechnology or Integration · 14 May 2025Global collaboration announced May 14, 2025, transforming early detection and proactive treatment of early dental decay. Pearl's AI enables dental practitioners to detect tooth decay earlier, while vVARDIS Curodont offers a drill-free solution to treat early stages of tooth decay.
• VideaHealthflagship / coreTechnology or Integration · 13 June 2024Commercial collaboration combining VideaHealth's AI-powered dental detection (VideaAI) with vVARDIS's Curodont Repair Fluoride Plus for end-to-end early detection and drill-free treatment. Over 400,000 patients identified with early caries through VideaAI have been treated with Curodont, demonstrating 90%+ success rate in treating early caries.
• Prestigious universities and dental schoolscoreStrategic or Co-development PartnervVARDIS partners with prestigious universities and dental professionals to advance research, support clinical studies, and progressively integrate Curodont technology into dental school curricula. The company's technology has been peer-reviewed in 230+ publications.
• National Academy (sustainability in dentistry)minorStrategic or Co-development PartnervVARDIS products are included in the National Academy Training program focused on sustainability in dentistry, providing ESG-aligned training and education for dental professionals.
• Heartland DentalcoreChannel Partner/ Reseller/ DistributorHeartland Dental (1,800+ practices across 39 states + DC) integrated advanced AI and biomimetic technologies including vVARDIS Curodont in 2024, expanding partnerships in 2025 as one of the major DSOs adopting Curodont across its supported practices.

Scale indicators11 records

Recent moves7 records

Expansion highlights8 records

Broad incumbents

• Dentsply Sirona: Largest pure-play dental equipment and consumables company globally; supplies preventive and restorative materials (including fluoride, glass ionomers, and remineralization products) that compete for the same chairside minutes and DSOs as vVARDIS's Curodont. Comparable because it operates across the same dental practice and DSO buyer base, even though its biomimetic peptide exposure is limited.
• 3M Oral Care (Solventum): Major dental materials and preventive care business (now part of Solventum) offering fluoride varnishes, sealants, and restorative products sold to the same U.S. dental practices and DSOs that vVARDIS targets. Comparable as a broad incumbent with overlapping preventive-care channels and the capital to bundle competing products.
• GC Corporation: Japanese-headquartered dental materials manufacturer whose MI Paste / Recaldent (CPP-ACP) line is a competing chairside remineralization/early-caries product. Most directly comparable incumbent on the 'non-invasive early lesion treatment' category vVARDIS competes in.

Emerging players

• Ultradent Products: U.S. dental materials manufacturer with a strong preventive and minimally invasive portfolio (e.g., enamel-strengthening and desensitizing products) sold to the same dental professionals as Curodont. Comparable as a specialist dental materials player competing for chairside early-intervention minutes.
• VOCO: German dental materials company specializing in preventive and restorative products, including remineralization and sealants. Comparable to vVARDIS as a specialist competitor in early caries intervention and minimally invasive dental materials sold through professional channels.
• BISCO: U.S. dental materials manufacturer focused on adhesive, resin, and preventive products sold to general dentists and specialists. Comparable as a specialist dental materials company competing for chairside early-intervention share and DSO contracts.
• DMG Dental: German dental materials manufacturer with a portfolio including preventive and minimally invasive products sold to dental professionals globally. Comparable to vVARDIS in its focus on preventive/minimally invasive dentistry and DSO-relevant professional channels.
• Premier Dental: U.S. dental products company offering preventive, restorative and hygiene products to general dentists and DSOs. Comparable as a specialist dental materials company with overlapping buyer base and product categories (prevention, remineralization).
• Pearl (Pearl AI): AI dental imaging company with Second Opinion / Pearl AI detection software that flags early caries on dental x-rays — a current vVARDIS commercial partner. Comparable as a participant in the AI-powered early caries detection workflow that feeds Curodont treatments.
• VideaHealth: AI dental caries detection company (VideaAI) that is a commercial partner with vVARDIS, having routed 400,000+ patients into Curodont treatment. Comparable as a participant in the same AI-detection-to-treatment workflow that drives vVARDIS's same-day chairside adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vvardis
• Instagraminstagram.com/vvardis.professional

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about vVardis